Investor Relations

Amicus Therapeutics (NASDAQ: FOLD) is pioneering a paradigm-shifting approach to treating a range of human genetic diseases in which crucial proteins are misfolded, thus reducing or eliminating their functionality. Amicus develops pharmacological chaperones - oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. This novel, next-generation approach offers the potential to improve treatment options for patients with genetic diseases.

2010 Proxy Materials

Recent Releases

May 10, 2012
Amicus Therapeutics Announces First Quarter 2012 Financial Results

May 4, 2012
Amicus Therapeutics to Announce First Quarter 2012 Financial Results on May 10, 2012

more »

Events

May 10, 2012
Amicus Therapeutics First Quarter 2012 Results Conference Call

Feb 29, 2012
Amicus Therapeutics to Present at 2012 RBC Global Healthcare Conference

more »